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Abbreviations 
 
HF: heart failure;  
 
LV: left ventricular;  
 
OXPHOS: oxidative phosphorylation; 
 
mtDNA: mitochondrial DNA; 
 
MIC: mitochondrial cardiomyopathies; 
 
LCM: laser capture microdissection; 
 
COX: cytochrome c oxidase; 
 
SDH: succinate dehydrogenase; 
 
TEM: transmission electron microscopy; 
 
PPAR: peroxisome proliferator-activated receptor alpha, PPARA;  
 
PGC-1: peroxisome proliferator-activated receptor gamma, coactivator 1 alpha, PPARGC1A; 
 
NPPA: natriuretic peptide A; 
NRF1: nuclear respiratory factor 1;  
ERRα: estrogen-related receptor alpha, ESRRA;  
TFAM: mitochondrial transcription factor A;  
POLG: polymerase (DNA directed) gamma;  
HPRT1: hypoxanthine phosphoribosyltransferase 1;  
SDS-PAGE: sodiumdodecylsulphate–polyacrylamide gel electrophoresis; 
PVDF: polyvinylidene fluoride;  
DNPH: 2,4-dinitrophenylhydrazine;  
 
DNP: antidinitrophenyl;  
 
CAT: catalase; 
 
GPx: glutathione peroxidase;  
 
NADPH: nicotinamide adenine dinucleotide phosphate;  
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SOD2: superoxide dismutase 2; 
 
MDA: malondialdehyde. 
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Abstract 
Mitochondrial (mt) DNA depletion and oxidative mtDNA damage have been implicated in the 
process of pathological cardiac remodeling. Whether these features are present in the early phase of 
maladaptive cardiac remodeling i.e. during compensated cardiac hypertrophy, is still unknown.  
We compared the morphologic and molecular features of mitochondrial biogenesis and markers of 
oxidative stress in human heart from adult subjects with compensated hypertrophic cardiomyopathy 
and heart failure. We have shown that mtDNA depletion is a constant feature of both conditions. A 
quantitative loss of mtDNA content was associated with significant down-regulation of selected 
modulators of mitochondrial biogenesis and decreased expression of proteins involved in mtDNA 
maintenance. Interestingly, mtDNA depletion characterized also the end stage phase of 
cardiomyopathies due to a primary mtDNA defect. Oxidative stress damage was detected only in 
failing myocardium.  
 
Key words: cardiac remodeling, myocardial hypertrophy, mtDNA depletion, mitochondrial 
biogenesis, oxidative stress, and mitochondrial cardiomyopathy 
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1. Introduction 
Heart failure (HF) is a complex chronic clinical syndrome and a leading cause of morbidity and 
mortality in industrialized countries worldwide [1]. Central to the pathogenesis of HF is left 
ventricular (LV) contractile dysfunction, due either to an ischemic insult (i.e myocardial infarction), 
or to non-ischemic causes (e.g. hypertension, valvular heart diseases, genetic cardiomyopathies, 
etc.). These insults induce an inexorable series of maladaptive phenomena that manifest clinically 
as changes in the size, shape, and function of the heart, collectively referred to as pathological 
cardiac remodeling. The initial event in pathologic remodeling is left ventricular hypertrophy, 
which eventually evolves to left ventricular dilation and decreased contractility [2]. 
Clinical and experimental studies have shown that both impaired oxidative phosphorylation 
(OXPHOS) and increased mitochondria-derived oxidative stress are implicated in the 
pathophysiology of HF [see for a Review 3, 4]. Thus, the causes of mitochondrial dysfunction in 
HF are the object of intense investigations, in view of possible therapeutic applications [5]. Previous 
studies have pointed to altered mitochondrial biogenesis as one of the causal mechanisms of 
OXPHOS dysfunction in cardiac remodeling. Down-regulation of specific genes (i.e. peroxisome 
proliferator-activated receptor alpha, PPARA aliases PPAR; peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha, PPARGC1A aliases PGC-1) involved in energy metabolism 
modulation and mitochondrial biogenesis has been shown in several experimental models of HF [6-
11]. However, recent works suggest that the mechanisms at play are more complex in human than 
in animal models. For example, Karamanlidis et al. showed that mitochondrial dysfunction in the 
failing human heart is attributable to mitochondrial DNA (mtDNA) depletion rather than decreased 
transcriptional activity of the mitochondrial genome [12] and pointed to altered mtDNA replication 
and oxidative-dependent mtDNA damage as possible mechanisms. In addition, an unresolved issue 
with potential therapeutic implications is whether, and to what extent, the derangement in 
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mitochondrial biogenesis observed in HF is present in the early phase of cardiac remodeling, i.e. 
during compensated hypertrophy.  
In the present work we aimed to evaluate mitochondrial biogenesis and oxidative damage in 
compensated myocardial hypertrophy and HF in the adult human heart. To this purpose we 
compared ultrastructural, biochemical and molecular features of myocardial samples from patients 
with sarcomeric hypertrophic cardiomyopathy (as a model of compensated myocardial hypertrophy) 
and end-stage ischemic cardiomyopathy. For further comparison, we looked for changes in 
mitochondrial biogenesis and oxidative stress in hypertrophic non-failing and failing hearts 
associated with a primary mtDNA defects (all patients with mitochondrial tRNA mutations). 
 
2. Materials and Methods 
 
2.1. Patients 
All studies conformed to Sapienza, University of Rome Ethical Committee protocols. 
Hypertrophic, non-failing, myocardial samples were obtained from septal myectomy procedures 
performed on patients with sarcomeric hypertrophic cardiomyopathy with obstructive physiology 
(HCM group, n= 10). Left ventricular myocardial samples from patients with end-stage heart failure 
(HF group, n=15) were obtained from transplant procedures. We selected only failing hearts with 
proven ischemic etiology based both on clinical records and gross morphologic findings. We used 
as controls (NHF group) left ventricular myocardial samples obtained either from donor hearts, 
which were unsuitable for transplantation (n = 5) or from autopsies of subjects who died for non-
cardiac causes (i.e. traffic accident), obtained from the Forensic Pathology Service, Institute of 
Legal Medicine of Seville, Spain (n=5, obtained within 4 hours from death).  
In addition, we analyzed left ventricular myocardial samples obtained either at autopsy 
(performed within four hours from death, n=3) or cardiac transplant (n=3) from patients with 
genetically proven mitochondrial cardiomyopathies (MIC). 
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2.2. Gross analysis, histology and enzyme histochemistry  
All explanted hearts were weighted and photographed. The epicardial coronary arteries were 
examined and the presence and degree of luminal narrowing evaluated. The myocardium was 
carefully inspected with short axis sections. Myectomy samples from HCM patients were grossly 
inspected and measured after surgery.  
For routine histological analysis multiple samples from the left ventricle, ventricular septum 
and coronary arteries were embedded in paraffin, and 5-micronmeter-thick sections were stained 
with hematoxylin-eosin, periodic acid– Schiff (PAS) and Masson trichrome stain.  
Myocardial samples from left ventricle and myectomy were collected, avoiding areas of scarring, 
and immediately snap-frozen in liquid nitrogen-chilled isopentane, both in cryovials for molecular 
analyses and in OCT embedding compound for enzyme histochemistry and laser capture 
microdissection (LCM) experiments.  
To identify mitochondrial respiratory chain deficient cardiomyocytes, we performed sequential 
cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) reactions on frozen sections from 
the left and right ventricles. Combining the histo-enzymatic mitochondrial reactions for COX 
(brown) and SDH (blue) normally results in a brown precipitate within the cell in the presence of 
normal COX activity. As a consequence of mtDNA depletion and/or multiple deletions, 
mitochondrial protein synthesis is impaired, resulting in a significant reduction in COX activity. In 
contrast, activity of the entirely nuclear-encoded SDH is retained. Thus, cells with mtDNA defects 
are highlighted as blue, respiratory-deficient cells following the sequential COX/SDH reaction. 
 
2.3. Ultrastructural and morphometric analysis  
Mitochondrial ultrastructure was studied in myocardial samples by transmission electron 
microscopy (TEM). Two-mm
3 
myocardial blocks were dissected from 3 hearts from each study 
group and immediately fixed in 2.5% phosphate buffered glutaraldehyde. Tissue dehydration, resin 
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embedding and staining were performed as described [13]. Grids were observed with a Zeiss EM 10  
(ZEISS Obercocken, Germany) (TEM) and 15 random fields at 8000x magnification were acquired 
and stored as TIFF images (Digital Micrograph 3.4TM, Gatan GMBH, Munchen, Germany). Image 
analysis was performed using ImageJ 64 1.48a (GNU License, National Institute of Health, 
Bethesda MD, USA). Mitochondria were counted, the perimeter of each organelle was manually 
traced and the mitochondrial area was automatically measured. Both the total and the mean cross-
sectional mitochondrial area were then obtained for each acquired field. The sarcomere area was 
also manually measured for each image and the ratio between total mitochondrial area and 
sarcomere area was then derived.  
 
2.4. Molecular analyses 
Prior to each experiment, sections stained with hematoxylin and eosin and Masson trichrome 
stain were obtained from each frozen myocardial sample for morphological examination, to exclude 
the presence of extensive fibrosis.  
Total DNA from LV myocardial tissue was extracted by Wizard Genomic DNA Purification Kit  
(Promega, Madison, WI, USA). Total RNA was isolated from LV tissue using the SV total RNA 
isolation kit (Promega, Madison, WI, USA). RNA amount was measured with NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Inc. Wilmington, DE USA) and total RNA was 
reverse-transcribed to cDNA using System Capacity cDNA Reverse Transcription Kits (Applied 
Biosystems, Life technologies Italia, MB, Italy) according to manufactures guidelines. 
 
2.5. Quantification of mtDNA and laser capture microdissection analysis 
Total DNA was obtained both from myocardial homogenates and from myocytes microdissected by 
LCM (Leica LMD 7000, Leica Microsystem, MI, Italy). For the latter, serial 5-m-thick frozen 
sections were mounted on a polyethylene foil slide and stained with hematoxylin and eosin. 
Sections were observed under light microscope with a 40X objective. Small groups of myocytes (5-
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10 cells) were microdissected by an UV laser and collected on an adhesive cap of nanotubes as 
previously described [14]. Samples were digested with proteinase K (25g/100l) over night at 
37°C, pre-amplified by TaqMan
®
 PreAmp Master Mix kit (Life Technologies Italia, MB, Italy) 
according to manufactures guidelines. Absolute quantification of mitochondrial DNA was 
performed by the standard curve method as previously detailed [14]. The technique involves 
obtaining the ratio of an unknown variable (number of copies of mtDNA) to a known factor 
(number of copies of a nuclear DNA gene). With each assay, a standard curve for mtDNA and 
nDNA was generated using serial known dilutions of a vector in which the regions used as template 
for the two amplifications were cloned tail to tail, to have a ratio of 1:1 of the reference molecules 
[15]. The absolute mtDNA copy number per cell was obtained by the ratio of mtDNA to nDNA 
values multiplied by 2 (as two copies of the nuclear gene are present in a cell). Evaluation of 
mtDNA content in cardiac homogenate was performed by quantitative-Real Time PCR (qRT-PCR) 
as described [15], and expressed as mtDNA/nuclear DNA ratio.   
 
2.6. Gene expression analysis by quantitative real time PCR 
The relative expression of the following genes was evaluated by quantitative RT-PCR using 
TaqMan probe chemistry by means of inventoried and custom FAM- labeled TaqMan MGB probe 
(Life Technologies Italia, MB, Italy) according to the manufacturer’s instructions (Supplemental 
table 1): natriuretic peptide A (NPPA), a molecular marker of cardiac hypertrophy; PPAR-, a 
critical regulator of cardiac oxidative metabolism; PGC1-, nuclear respiratory factor 1 (NRF1), 
estrogen-related receptor alpha (ESRRA aliases ERRα), important regulators of mitochondrial 
biogenesis; mitochondrial transcription factor A (TFAM) and polymerase (DNA directed) gamma 
(POLG), core components of the mitochondrial transcription and replication machinery. In all 
samples, the relative expression of each target gene was evaluated with the comparative threshold 
cycle (ΔCt) method respect to one control (reference sample) and normalized to the hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) rRNA housekeeping gene.  
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2.7. Western blot analysis  
Frozen myocardial tissue was homogenized with the RIPA lysis buffer [50mM tris-HCl 
pH8, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1% sodium dodecyl sulphate (SDS), 
1mM phenylmethylsulfonyl fluoride, 10mg/ml aprotinin, 10mg/ml leupeptin and mg/ml pepstatin] 
and centrifuged at 14000g for 10 min at 4°C. The protein concentration was measured by protein 
assay (Bio-rad Laboratories s.r.l, Hercules, CA). Equal amount of protein (40µg) was separated by 
12% sodiumdodecylsulphate–polyacrylamide gel electrophoresis (SDS-PAGE) or precast 4-
20%Bolt
TM 
Mini Gels (Invitrogen 
TM
, Life Technologies Italia, MB, Italy) and transferred to a 
polyvinylidene fluoride (PVDF) membrane. The following primary antibodies were used: anti-
mouse monoclonal PGC-1α  (Calbiochem, Millipore, MA, USA); anti rabbit monoclonal ERRα 
(Abcam, Cambridge, UK); anti rabbit polyclonal TFAM (ATLAS antibodies AB, AlbaNova 
University Center, Stockholm, Sweden); anti mouse β-Actin (-Aldrich, St-Louis, MO, USA). 
Primary antibodies were visualized using horseradish peroxidase-conjugated secondary antibodies 
(Jackson ImmunoResearch, laboratories, inc. USA). Signals were detected by enhanced 
chemiluminescence (Promega corporation, Madison, WI, USA). 
 
2.8. Oxyblot procedures 
Total myocardial protein carbonylation was measured using the OxyBlot Protein Oxidation 
Detection Kit (Chemicon, Millipore, MA, USA) according to the manufacturer’s protocol. Briefly, 
carbonyl groups were derivatized by reaction with 2,4-dinitrophenylhydrazine (DNPH) for 15 min. 
Dinitrophenyl-derivatized proteins were resolved by 12% SDS-PAGE and transferred to a PVDF 
membrane. Membranes were incubated 1h at room temperature with antidinitrophenyl (DNP) 
primary antibodies (1:150) and then with goat anti-rabbit IgG (HRP conjugated) antibodies (1:300) 
for 1h.  
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2.9. Antioxidant enzyme activities 
Antioxidant enzymes activities were evaluated as previously reported [16]. Briefly, for catalase 
(CAT) activity, 70 g of tissue homogenates was added to 100 mM phosphate buffer, pH 6.8, 
containing 10 mM H2O2. CAT activity was determined following the decrease in absorbance at 240 
nm of H2O2 for 30 s at 25 °C [17]. The activity was calculated using a H2O2 extinction coefficient 
of 43.6×103 M−1×cm−1and was expressed as μmol/min/mg of protein.
For glutathione peroxidase (GPx) activity, 70 g of tissue homogenate was added to 100 mM 
phosphate buffer, pH 7.4, containing 0.5 mM EDTA, 1.0 mM NaN3, 0.25m MNADPH, 
2.25mMGSH, 1.0 U/ml glutathione reductase. After addition of 0.24 mM tert-butil hydroperoxide 
(Sigma-Aldrich, St-Louis, MO, USA), the change in optical density of NADPH was monitored 
spectrophotometrically at 340 nm for 2.0 min at 25 °C [18]. GPx activity was calculated using a 
molar extinction coefficient for NADPH of 6.22×103 M−1×cm−1 and expressed as nmol/min/mg 
protein. 
Superoxide dismutase 2 (SOD2) activity was evaluated in 10 μg of tissue homogenate using a 
Chemical Superoxide Dismutase Assay kit (Cayman Chemical, Ann Arbor, Michigan) as described 
[18]. Enzymatic activity was expressed as Units/mg of protein.  
2.10. Lipid peroxidation 
Oxidative stress level was evaluated by measuring malondialdehyde (MDA) concentration, 
as a marker of lipid peroxidation. A Bioxytech LPO-586 (Oxis International Inc.  Prodotti Gianni, 
Milano, Italy) was used. 
2.11. Statistical analysis 

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3. Results 
3.1. Characterization of the study population 
Characteristics of the study population are reported in Table 1. Briefly, patients with end-
stage heart disease (HF group) were slightly older than patients with hypertrophic cardiomyopathy 
and controls (mean age of HF group 57 years, vs. 45 and 43 years of age for the HCM and NHF
patients respectively).  All HF patients were in NYHA 3/4 while patients with HCM were in NYHA 
1/2. The mean ejection fraction (EF) in HF group was lower than 25% while it was within normal 
limits in HCM and NHF groups, as expected. As molecular markers of myocardial hypertrophy and 
heart failure, we evaluated the gene expression level of NPPA. As expected increased levels NPPA
were observed in ventricular samples obtained from hypertrophic and failing hearts (Supplemental 
Figure 1). 
3.2. Morphologic features  
 Gross and histologic evaluation confirmed the clinical diagnosis in all explanted hearts from 
patients with ischemic cardiomyopathy: in 10 cases (66%) there was severe atherosclerosis of the 
epicardial coronary arteries, complicated by transmural myocardial infarction. In five hearts (33%) 
there was diffuse intramural coronary artery disease, with multiple small myocardial scars in the 
absence of significant stenosis of the major epicardial vessels. Surgical samples from myectomy 
procedures in patients with hypertrophic cardiomyopathy showed marked myocytes hypertrophy 
and disarray, along with a mild increase in interstitial collagen and focal microvascular disease,
consistent with the diagnosis of sarcomeric HCM. Control hearts were unremarkable, both on gross 
and pathologic examination. Sequential COX/SDH reactions, performed to identify respiratory 
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chain deficient cardiac myocytes in the three groups, showed rare, scattered (<1 per high power 
field) COX-deficient cells in the left ventricle of all HF samples and in 8/10 HCM samples. COX-
deficient cells were never observed in controls (Figure 1A). 
 
3.3. Hypertrophic and failing heart shows partial mtDNA depletion 
As a marker of mitochondrial biogenesis we first analyzed the mtDNA amount of whole 
heart homogenates in the three groups.  We showed a 30% decrease of mtDNA content (expressed 
as mtDNA/nuclear ratio) both in HCM (n=10) and HF (n=15) as compared with NHF (n=10). This 
was paralleled by a decreased expression of the mitochondrial gene MTCOI, coding for a subunit of 
complex IV of the respiratory chain (Figure 1B and 1C). Since cardiac homogenate is not only 
composed of cardiomyocytes but also of other tissues components (i.e. fibrosis, vessels, etc.) that 
may be differently represented in the three study groups, we performed laser capture 
microdissection on frozen cardiac sections to selectively measure the mtDNA amount in 
cardiomyocytes. By this technique we confirmed the significant mtDNA reduction in HF (57% 
decrease as compared with controls) while there was a less pronounced reduction (19%) in HCM 
(Figure 1D and 1E).  
 
3.4. Partial mtDNA depletion is associated with reduced expression of proteins involved in   
mtDNA replication  
 We then evaluated the hypothesis that reduced mtDNA content in hypertrophic and failing 
hearts could be related to reduced mitochondrial biogenesis. Accordingly, we measured the relative 
expression levels of genes involved in mitochondrial biogenesis. As shown in Figure 2A, PGC-1, 
the master regulator of mitochondrial biogenesis, was unchanged both in HCM and HF, while 
selected transcriptional regulators that PGC-1 co-activates behaved differently. In fact, both NRF1 
and ERR appeared reduced in both conditions (up to 25% decrease), while PPAR levels were 
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unchanged. Finally, reduction of both TFAM, the key regulator of mtDNA transcription and 
mitochondrial polymerase POLG gamma, was observed both in HCM and HF (Figure 2B). 
Western blot analysis confirmed a clear reduction of TFAM protein in both HCM and HF groups 
while PGC-1 was unchanged. However, possibly because of the small data set and the intrinsic 
inter-individual variability, differences in protein levels between groups did not reach statistic 
significance (Figure 2C).
3.5. Cardiomyocytes from hypertrophic and failing heart show increased number and 
reduced size of mitochondria  
We performed ultrastructural morphometric analysis on a subset of myocardial samples 
(NHF=3; HCM=3; HF=3) to evaluate both density and morphology of mitochondria. A mean of 
1251 isolated mitochondria  (defined as organelles enclosed by a double contoured membrane) were 
analyzed from each sample  (range 940-1690; SD  326.16). As shown in Figure 3A mitochondria 
in HCM and HF were increased in number and appeared smaller as compared with controls. These 
features were more marked in HCM. In fact, the absolute number of mitochondria per area was 
increased by 96% in HCM and 35% in HF (Figure 3B) while the mean cross-sectional area of 
individual mitochondria was reduced by 70% in HCM and 39% in HF, as compared with controls 
(Figure 3C). To assess if the observed mitochondrial remodeling in cardiac hypertrophy and failure 
reflected changes in the total mitochondrial volume mass we evaluated 
3.6. Markers of oxidative stress and antioxidant enzyme activities are increased only in end-
stage failing hearts  
Since myocardial oxidative damage has been implicated both in mtDNA damage and in the 
progression to heart failure, we looked for markers of oxidative stress in HCM and HF. Both 
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3.7. Mitochondrial cardiomyopathies show mtDNA depletion in the end-stage phase. 
Based on electrocardiographic 
and echocardiographic features (Table 3) patients were divided into two groups, MIC with 
compensated cardiac hypertrophy (H MIC, n=3) and end-stage MIC (HF MIC, n=3).  
Consistent with the mitochondrial etiology, combined COX/SDH reactions on frozen heart sections 
showed a mosaic pattern of COX-positive and COX-deficient cells, with a prevalence of the latter 
in presence of mutation levels above 90% (Figure 5A). The more interesting result, at molecular 
analysis, was the significant in
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4. Discussion 
Despite significant progress in cardiovascular medicine, heart failure remains a leading cause of 
morbidity and mortality in industrialized countries. Failing hearts invariably show abnormal energy 
metabolism, increased ROS production and mitochondrial respiratory chain dysfunction [20-21].
These are associated with impaired mitochondrial biogenesis, suggesting that mitochondria-targeted 
therapies may be effective in heart failure [22]. Important and unresolved issues are whether 
impaired mitochondrial function and biogenesis are present already in the early stage of myocardial 
remodeling, i.e. during compensated hypertrophy, and which is the underlying pathogenic 
mechanism.   
Studies on animal models show that deregulation of mitochondrial biogenesis is an early event in 
heart failure, and appears to be triggered by down-regulation of the PGC-1 pathway [6, 7, 9, 10].
However, results obtained in animal models have not been verified in human, due to the difficulties 
in obtaining surgical cardiac tissue samples from patients with compensated hypertrophy. In a 
previous study Karamanlidis et al. [23] analyzed mitochondrial biogenesis in myocardial samples 
from hypertrophic and failing right ventricles of pediatric patients undergoing surgery for 
congenital heart disease. According to their results both the hypertrophic and failing ventricles 
showed a lower mtDNA content as compared to normal hearts, suggesting that mitochondrial 
dysfunction is involved in both processes of compensated hypertrophy and overt heart failure. 
However, the age difference between subjects with heart failure (median age: 0.8 months), 
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compensated hypertrophy (median age: 6.3 years) and controls (median age: 12 years) could by 
itself account for some of the observed changes and made results difficult to interpret [24]. The 
reported higher amount of mtDNA in control subjects, as compared with patients with compensated 
hypertrophy and heart failure, could reasonably be due, at least in part, to the induction of 
mitochondrial biogenesis during heart growth [25, 26]. 
In the present study, we focused our analysis on adult subjects. We compared mitochondrial 
biogenesis and markers of oxidative stress in myocardial samples from patients with either 
sarcomeric HCM (as a model of compensated myocardial hypertrophy) or end-stage ischemic 
cardiomyopathy, with age-matched controls. We showed that mtDNA depletion and decreased 
levels of proteins involved in mtDNA maintenance are common features to both conditions, 
suggesting that impaired mitochondrial biogenesis is an early event in cardiac hypertrophic 
remodeling. mtDNA depletion in HCM was more evident in the total heart homogenate as 
compared with dissected cardiac myocytes. A likely explanation for this observation is that the 
mtDNA content in total heart homogenate derives both from cardiac myocytes and interstitial cells 
(i.e. fibroblast, endothelial and smooth muscle cells). In fact, interstitial tissue is invariably 
increased in HCM [27, 28].  According to their low energy requirement, interstitial cells are 
expected to have lower mtDNA amount as compared to cardiac myocytes [29, 30]. Thus, the total 
mtDNA amount in HCM homogenates may be “diluted” by the interstitial cells.  
Changes in mtDNA levels were paralleled by down-regulation of the key modulators of 
mitochondrial biogenesis NRF1, ERR, TFAM and POLG1 but not of PGC-1, as previously 
reported in heart failure [12, 31]. 
Both in compensated hypertrophy and in heart failure, the decrease in mtDNA content is paralleled 
by an increase in the number of intermyofibrillar mitochondria, that appear smaller than controls, 
while the total mitochondrial mass is unchanged. The significance of these features is unclear and 
should be confirmed in a higher number of samples. Chen et al. [32] recently showed that the 
increased number of small mitochondria in heart disease is caused by an altered mitochondrial 
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fusion/fission balance and speculated that this may be related to increased myocyte apoptosis, 
contributing to heart failure.  
Since reactive oxygen species have been implicated as potential modulators of mitochondrial 
biogenesis [12] we then looked for markers of oxidative damage in myocardial samples from 
compensated hypertrophy and heart failure. Lipid peroxidation and protein carbonylation were 
raised exclusively in the failing myocardium and were associated with activation of 
All together our results show that impaired mitochondrial biogenesis is a constant feature of cardiac 
maladaptive remodeling being present both in compensated hypertrophic cardiomyopathy and in 
overt cardiac failure. Conversely oxidative stress damage is detected only in failing myocardium. 
Thus, oxidative stress damage seems not to be a causative factor of impaired mitochondrial 
biogenesis and mtDNA depletion in cardiac myocytes, at least in this setting.  
We then analyzed mitochondrial biogenesis and oxidative stress in cardiomyopathies caused by 
mutations in genes coding for mt-tRNAs. These mutations cause structural alteration and reduced 
stability of mt-tRNAs that affect whole mitochondrial protein synthesis, leading to a respiratory 
chain dysfunction. The net effect is the reduction in cellular energetic proficiency and the increase 
in mitochondrial-derived ROS production.  A common feature of mitochondrial disease caused by 
mtDNA mutations is the up-regulation of mitochondrial biogenesis, to overcome the decrease in 
ATP levels due to respiratory chain dysfunction [34, 35]. Accordingly, we observed induction of 
mitochondrial biogenesis in the hypertrophic phase of MIC. However, failing MIC showed mtDNA 
depletion and decrease of genes involved in mtDNA maintenance. Again, marked oxidative stress 
damage was evident only in the end stage hearts.  
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5. Conclusion 
 
In conclusion, altered mitochondrial biogenesis, mtDNA depletion and oxidative stress damage are 
constant features of heart failure irrespective of the underlying etiology. The mechanisms involved 
in deranged mitochondrial biogenesis and mtDNA depletion and the impact of this derangement on 
the progression of pathological cardiac remodeling still needs to be elucidated. Our results suggest 
that oxidative stress in not implicated in mediating mtDNA depletion, at least in the early phase of 
cardiac remodeling. 
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Figure Legends 
 
Figure 1. Combined COX-SDH histochemistry and mtDNA amount in myocardium from 
compensated hypertrophy and end-stage heart failure. 
A. Representative images of combined histochemical reactions for mitochondrial enzymes 
cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) in non-failing hearts 
(NHF), compensated hypertrophic cardiomyopathies (HCM) and failing hearts (HF). 
Scattered COX-deficient cardiac myocytes (blue) are observed in both HCM and HF (COX-
SDH stain, original magnification 20X) 
B. Mitochondrial DNA amount measured in cardiac homogenate of NHF (n=10), HCM (n=10) 
and HF (n=15) (expressed as mtDNA/nuclear DNA ratio). Both NHF and HCM show a 
significant reduction of mtDNA amount as compared to NHF. 
C. MTCO1 messenger RNA relative expression in cardiac homogenate of NHF, HCM and HF. 
Both HCM and HF show a reduction in MTCO1 level as compared to NHF.  
D. Mitochondrial DNA amount in cardiac myocytes microdissected by laser capture from NHF 
(n=8), HCM (n=6) and HF (n=7) (expressed as mtDNA copy per cardiac myocyte). A 
statistically significant reduction of mtDNA copies per cardiac myocyte is observed only in 
HF as compared to NHF.  
E. Representative image of myocardium before and after microdissection of single myocytes  
(hematoxylin and eosin stain, original magnification 40X) 
Experiments were performed in triplicate. Data are expressed as mean  SEM. *p<0.05; **p<0.01; 
***p<0.001 for HCM and HF versus NHF 
 
Figure 2. Expression levels of genes and proteins involved in mitochondrial biogenesis.  
A. Messenger RNA relative expression levels of PGC-1, NRF1, EER, PPAR. A significant 
decrease of NRF1 and EER was found in HF (dark gray) as compared to NHF. NRF1 
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levels were significantly decreased also in HCM (light gray) as compared to NHF.   
Experiments were performed in triplicate. 
B. Messenger RNA relative expression levels of TFAM and POLG. Both genes showed a 
general reduction, both in HF and HCM as compared to NHF. However the reduction was 
statistically significant for POLG in HF (dark gray), and TFAM in HCM (light gray). 
Experiments were performed in triplicate. 
C. Expression of selected proteins involved in mitochondrial biogenesis and mtDNA 
maintenance: representative western blot and densitometry are shown. Normalization 
relative to -actin (mean of three experiments), showed a generalized reduction of TFAM 
both in HCM and HF as compared to NHF. PGC-1 levels were similar in the three study 
groups. 
Data are expressed as mean  SEM and are normalized to the level of NFH (indicated by the line). 
*p<0.05; **p<0.01; for HCM and HF versus NHF 
 
Figure 3. Mitochondrial density and morphology, and citrate synthase activity. 
A. Representative ultrastructural images of NHF, HCM and HF samples. 
B. Graph summarizing the number of mitochondria per area (100µm2) in myocardium of NF 
(n=3), HCM (n=3) and HF (n=3). Number of mitochondria is significantly increased both in 
HCM and HF as compared to NHF. 
C. Graph summarizing the average mitochondrial size in myocardium of NHF, HCM and HF. 
The mean cross sectional area of mitochondria is significantly decreased both in HCM and 
HF as compared to NHF.  
D. Citrate synthase (CS) activity in cardiac homogenate from NHF, HCM and HF. Cytrate 
synthase activity was comparable in the three groups.  
Data are expressed as mean  SEM. ***p<0.001 for HCM and HF versus NHF  
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Figure 4. Markers of oxidative stress and antioxidant enzymes activity
Data are expressed as mean  SEM. ***p<0.001 for HF versus NHF   
Figure 5. Markers of mitochondrial function and biogenesis and levels of carbonylated 
proteins in mitochondrial cardiomyopathy 
A. Representative images of combined histochemical reactions for mitochondrial enzymes 
cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) in non-failing hearts 
(NHF), mitochondrial cardiomyopathy (MIC) with compensated cardiac hypertrophy (H 
MIC) and end-stage MIC (HF MIC).  A large amount of COX-deficient cardiac myocytes is 
observed both in H MIC and HF MIC. 
B. Mitochondrial DNA amount (mean  SEM) in NHF (n=8), H MIC (n=3) and HF MIC (n=3) 
evaluated on whole cardiac homogenate (left) and microdissected cardiac myocytes (right). 
Mitochondrial DNA depletion was observed in end-stage MIC, while a slight non significant 
increase mtDNA characterized microdissected cardiac myocytes from H MIC. 
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C. Messenger RNA relative expression levels of PGC-1, NRF1, ERR, TFAM and POLG in 
NHF (n=10), H MIC (n=2) and HF MIC (n=2). Level of ERR, TFAM and POLG were 
slightly increased in H MIC (light gray) as compared to NHF and HF MIC (dark gray). Data 
are expressed as mean  SEM and are normalized to the level of NFH (indicated by the 
line). 
D. Expression of selected proteins involved in mitochondrial biogenesis and mtDNA 
maintenance: representative western blot and densitometry are shown. Densitometry data 
are expressed as mean  SEM and are normalized to the level of NFH (indicated by the 
line).  
densitometry (mean SEM)
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Table 1. Characteristics of patients with compensated hypertrophic cardiomyopathy and end-
stage ischemic heart disease. 
 
 NHF (n=10) HCM (n=10) HF (n=15) 
Age in years, median (range) 43(17-72) 45(36-59) 57(45-67) 
Gender, male 7 7 14 
EF (%) 58±7
#
 63±4*** 24.6±2*** 
Cardiac Index (L/min/m
2
) na 2.87±0.43 2.28±0.04§§ 
PWP, mm Hg na 13.5±3.34 22.2±2.7§§§ 
PAP, mm Hg na 24.8±3.85 33.4±3.3§§§ 
Treatments 
Ace Inhibitors na 0 15 
-blockers na 3 13 
Statins na 0 3 
Associated disease 
Diabetes na 0 5 
Dyslipidaemia na 0 5 
Hypertension na 3 8 
 
Abbreviations 
NHF: non failing heart;  
HCM: hypertrophic cardiomyopathy;  
FH: failing heart;  
na: not available.  
#
: Ejection fraction (EF) refers only to the 5 heart donors.  EF values were not available for the 
autoptic cases. 
***p<0.001 vs NFH; §§ p<0.01 vs HCM; §§§ p<0.001 vs HCM 
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Table 2. Genetic and biochemical features of mitochondrial cardiomyopathies. 
 
Patient Phenotype mtDNA 
mutation 
% of 
mutation on 
heart 
homogenate 
Combined 
COX/SDH 
NPPA 
(mean±SEM) 
1 MELAS, Diabetes m.3243 A>G 
MTTL1 
77% Scattered COX-
negative fibers 
4.96±1.18 
2 MELAS m.3243 A>G 
MTTL1 
92% Prevalence of 
COX-negative 
fibers 
5.6±0.22 
3 MELAS m.3243 A>G 
MTTL1 
76% na na 
4 Cardiomyopathy, 
myopathy, CPEO, 
deafness 
m.3243 A>G 
MTTL1 
89% Prevalence of 
COX-negative 
fibers 
na 
5 (patient 
IV-09 in 
Taylor et 
al. 2003) 
Isolated MIC m. 4300 
A>G MTTI 
Homoplasmic Prevalence of 
COX-negative 
fibers 
62.18±0.54 
6 (Perli et 
al. 2012) 
Isolated MIC m.4277 C>T 
MTTI 
Homoplasmic Prevalence of 
COX-negative 
fibers 
28.12±0.8 
 
Abbreviations 
MELA: Smitochondrial encephalomyopathy, lactic acidosis, stroke-like episode;  
COX: cytochrome c oxidase;  
na: not available; 
MIC: mitochondrial cardiomyopathy;  
CPEO: chronic progressive external ophtalmoplegia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
31 
 
Table 3.  Clinical features of MIC patients. 
 
 
 Gender AD Cause 
of 
death 
ECG ECO Medication 
    Rhythm LVH Strain other EF% LVEDD LVESD LVWT 
VS  
LVWT 
PW 
 
 
H MIC 
1 M 35 SD sinus yes yes RVH N N N 16 15 BB, ACEi 
2 M 45 SD sinus yes yes no 45 N N N1 N1 ACEi 
3 M 36 SD sinus  
LBBB 
yes no Short 
PR 
55 44.5 34.5 12.5 9.5 BB, ACEi 
FH MIC 
4 M 30 CHF2 sinus, 
biventricular 
PM 
no no no 15 62 59 N1 N1 Dobutamine 
5 M 233 CHF sinus yes yes TWI 17 82 72 25 16 BB, ACEi 
6 M 203 CHF sinus yes yes TWI 25 69 63 21 18 BB, ACEi 
Abbreviations 
AD: age at death;  
LVH: left ventricle hypertrophy;  
EF: ejection fraction;  
LVEDD: left ventricular end-diastolic diameter;  
LVESD: left ventricular end-systolic diameter;  
LVWT: left ventricular wall thickness;  
VS: ventricular septum;  
PW: posterior wall;  
SD: sudden death;  
RVH: right ventricle hypertrophy;  
BB: beta blockers;  
ACEi: ACE inhibitors;  
LBBB: left bundle brank block;  
CHF: congestive heart failure;  
PM: pace maker;  
TWI: T-wave inversion;  
N: normal.  
1
Upper limit of normal; 
2
sudden death while waiting for cardiac transplant; 
3
cardiac transplant. 
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